Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. filed a Form 8-K reporting that Chief Operating Officer Jeffrey Millard submitted a resignation notice dated and effective July 10, 2026. The 8-K was filed on July 15, 2026 and discloses the departure under Item 5.02 (departure of certain officers).

Key Details

• Jeffrey Millard resigned from his role as Chief Operating Officer, resignation dated and effective July 10, 2026.
• The company disclosed the resignation in a Form 8-K filed July 15, 2026 (Item 5.02).
• The filing included an Inline XBRL cover page (Exhibit 104).
• The 8-K did not disclose a reason for the resignation or details about a replacement or compensatory arrangements.

Why It Matters
A change in senior management can affect execution of company operations and strategy; investors should note the removal of the COO role-holder. Because the filing provides no reason or successor information, stakeholders should watch for further SEC filings or company announcements that identify an interim or permanent replacement and any impact on operations or guidance.